logo
Form 8.3 - Revolution Beauty Group Plc

Form 8.3 - Revolution Beauty Group Plc

Business Wirea day ago

LONDON--(BUSINESS WIRE)--
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the 'Code')
1. KEY INFORMATION
(a) Full name of discloser:
cosnova Beauty GmbH
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
See 1(a)
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Revolution Beauty Group Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
N/A
(e) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
4 June 2025
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state 'N/A'
N/A
Expand
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary Shares (GB00BP7L1T61)
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
9,250,000
2.89
./.
(2) Cash-settled derivatives:
./.
./.
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
./.
./.
TOTAL:
9,250,000
2.89
./.
Expand
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
N/A
Details, including nature of the rights concerned and relevant percentages:
N/A
Expand
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchase/sale
Number of securities
Price per unit
Expand
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
Expand
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
Expand
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit
Expand
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
Expand
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state 'none'
none
Expand
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state 'none'
none
Expand
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
NO
Expand
Date of disclosure:
4 June 2025
Contact name:
Stephan Klinke
Telephone number*:
Expand
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Latecoere: Annual Shareholders' Meeting
Latecoere: Annual Shareholders' Meeting

Yahoo

time35 minutes ago

  • Yahoo

Latecoere: Annual Shareholders' Meeting

All resolutions submitted to the Annual Shareholders' Meeting were approved. TOULOUSE, France, June 10, 2025--(BUSINESS WIRE)--Regulatory News: The 2025 Annual General Meeting of LATECOERE (Paris:LAT) shareholders was held at the Company's registered office on June 6, 2025, and all resolutions submitted were approved. Detailed voting results are available on the Company's website: Regulated information - Latecoere. About Latecoere Tier 1 to the world's leading OEMs (Airbus, BAE Systems, Boeing, Bombardier, Dassault Aviation, Embraer, Honda Aircraft Company, Lockheed Martin, RTX, Thales), Latecoere serves aerospace with innovative solutions for a sustainable world. The Group operates in all segments of the aerospace industry (commercial, regional, business, defense and space) in three business areas: Aerostructures Europe and Americas: doors, fuselage, wings and empennage, rods; Interconnection Systems: wiring, avionic racks, on-board systems; Special Products and Services: customer services, on-board equipment, electronic systems. As of December 31, 2024, the Group employed 5,497 people in 14 countries. Latecoere is listed on Euronext Paris - Compartment B, ISIN Code: FR001400JY13 - Reuters: - Bloomberg: View source version on Contacts Media Relations Thierry Mahé+33 (0)6 60 69 63 85LatecoereGroupCommunication@ Investor Relations mandataires-ag-latecoere@ Sign in to access your portfolio

Latecoere: Annual Shareholders' Meeting
Latecoere: Annual Shareholders' Meeting

Business Wire

time44 minutes ago

  • Business Wire

Latecoere: Annual Shareholders' Meeting

TOULOUSE, France--(BUSINESS WIRE)--Regulatory News: The 2025 Annual General Meeting of LATECOERE (Paris:LAT) shareholders was held at the Company's registered office on June 6, 2025, and all resolutions submitted were approved. Detailed voting results are available on the Company's website: Regulated information - Latecoere. About Latecoere Tier 1 to the world's leading OEMs (Airbus, BAE Systems, Boeing, Bombardier, Dassault Aviation, Embraer, Honda Aircraft Company, Lockheed Martin, RTX, Thales), Latecoere serves aerospace with innovative solutions for a sustainable world. The Group operates in all segments of the aerospace industry (commercial, regional, business, defense and space) in three business areas: Aerostructures Europe and Americas: doors, fuselage, wings and empennage, rods; Interconnection Systems: wiring, avionic racks, on-board systems; Special Products and Services: customer services, on-board equipment, electronic systems. As of December 31, 2024, the Group employed 5,497 people in 14 countries. Latecoere is listed on Euronext Paris - Compartment B, ISIN Code: FR001400JY13 - Reuters: - Bloomberg:

Agenus Announces Virtual Annual Shareholders Meeting
Agenus Announces Virtual Annual Shareholders Meeting

Business Wire

timean hour ago

  • Business Wire

Agenus Announces Virtual Annual Shareholders Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. ('Agenus') (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests. Webcast Information: Time: 10:30 a.m. ET A live webcast and replay will be accessible on the Company's website at and at Voting Information: Shareholders of Agenus as of the April 24th, 2025, record date can vote. Alliance Advisors, Agenus's proxy solicitor, can assist shareholders with voting at 844-202-6561 or AGEN@ About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store